Nautilus Biotechnology Inc

The company maintains a strong liquidity position, with a current ratio of 19.69, indicating a high ability to meet short-term obligations. It has no long-term debt and holds $24.89 million in cash and equivalents, which is a significant portion of its total assets of $272.75 million. The price-to-book ratio of 1.42 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. In terms of profitability, the company reported a net loss of $18.01 million and an operating loss of $20.79 million in the latest period. The return on equity (ROE) is -7.65%, and the return on assets (ROA) is -6.6%, both indicating a negative return on invested capital. These figures are below the industry median for ROE and ROA, which are typically positive for profitable biotechnology firms. Geographically, the company's revenue is not disclosed by region, but its operations are primarily based in the United States. The company does not report revenue by business segment, which limits visibility into the performance of its various product lines. The company's growth trajectory is constrained by its current financial performance, with no significant revenue growth reported. The outlook for the current fiscal year does not indicate a material change in revenue, and the next fiscal year is expected to show similar trends. The company's operating cash flow is negative at -$31.72 million, and free cash flow is also negative at -$18.01 million, indicating that the company is not generating sufficient cash from operations to fund its activities. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. The capital structure is relatively simple, with no long-term debt and a high proportion of equity, which reduces financial risk. Recent events include analyst estimates that suggest a mean price target of $4.00, with a median and high target also at $4.00. The mean recommendation is 1.50, indicating a generally positive outlook from analysts. No recent filings or transcripts have been identified that would significantly alter the company's current financial or operational status.